Newswire (Published: Tuesday, October 31, 2017, Received: Thursday, October 26, 2017, 3:01:05 PM CDT)
Word Count: 402
Reports Summarize Prostate Cancer Study Results from Department of Radiation Oncology (Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy)
By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news originating from Florence, Italy, by NewsRx correspondents, research stated, "This multicenter, retrospective, 'field-practice' study investigated treatment outcomes of ongoing abiraterone therapy with the addition of radiotherapy (RT) - initiated for oligoprogression or with a palliative intent. Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate were considered if they had received RT after the initiation of abiraterone treatment."
Our news journalists obtained a quote from the research from the Department of Radiation Oncology, "A total of 32 patients were enrolled in the study. Median duration of abiraterone treatment was 13.0 months (range=3.8-40.9 months). Median duration of abiraterone treatment before RT was 5.9 months (range=0.4-40.0 months), and 7.2 months after RT (range=0.1-29.7 months). Median progression-free survival (PFS) was 12.6 months (95% CI=10.5-14.7) from the initiation of abiraterone treatment. From RT administration, PFS was 9.6 months (95% CI=6.4-12.9). Median overall survival (OS) since abiraterone initiation was 18.9 months (95% CI=4.7-33.0)."
According to the news editors, the research concluded: "RT prolongs abiraterone treatment in mCRPC patients leading to better clinical outcomes with this molecule."
For more information on this research see: Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy. Anticancer Research, 2017;37(7):3717-3722. Anticancer Research can be contacted at: Int Inst Anticancer Research, Editorial Office 1ST Km Kapandritiou-Kalamou Rd Kapandriti, PO Box 22, Athens 19014, Greece. (International Institute of Anticancer Research - www.iiar-anticancer.org/; Anticancer Research - www.iiar-anticancer.org/main.php?id=2)
The news correspondents report that additional information may be obtained from E. Olmetto, AOU Careggi, Dept. of Radiat Oncol, Florence, Italy. Additional authors for this research include R.M. D'Angelillo, G. Ingrosso, B. Detti, G. Francolini, L. Triggiani, A. Bruni, S. Borghesi, S. Fondelli, T. Carfagno, R. Santini, R. Santoni, L.E. Trodella and L. Livi (see also Oncology - Prostate Cancer).
Keywords for this news article include: Florence, Italy, Europe, Prostatic Neoplasms, Prostate Cancer, Therapeutics, Radiotherapy, Oncology, Therapy, Department of Radiation Oncology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies